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Abstract 
Background: End stage renal failure (ESRF) has become a major health problem in Sub Saharan Africa (SSA). There 
were limited data about causes of ESRF in the Sudan.
Methods: This is a cross sectional hospital based descriptive study. The subjects of the study are ESRF adults’ patients 
on regular haemodialysis treatment in 15 haemdoialysis centres in Khartoum State—Sudan. Clinical and epidemio-
logical data were obtained from 1583 patients. The medical files of each patient were reviewed to identify the cause 
of ESRF. Concerning the causes of ESRF, diabetes was diagnosed based on the past medical history and result of the 
glucose tolerance test, hypertension was diagnosed based on past history of hypertension based on blood pressure 
of more than 140/90 mmHg, glomerulonephritis was diagnosed based on results of previous kidney biopsies and on 
clinical grounds, polycystic kidney disease and obstructive uropathy were diagnosed based on abdominal ultrasound 
and other imaging modalities, sickle cell anaemia was diagnosed based on the result of haemoglobin electrophoresis, 
systemic lupus erythematosus was diagnosed based on the clinical criteria in addition to lab results of auto antibod-
ies, and analgesic nephropathy was diagnosed based on past medical history of chronic analgesic drugs usage with 
no other identifiable risk factors. We included all ESRF patients on regular haemodialysis treatment. We excluded ESRF 
patients less than 18 years old.
Results: The results showed that the mean age of ESRF Patients was 49 ± 15.8 (years) and 63.4 % were male and 
76.3 % were unemployed. The mean duration of haemodialysis is 4.38 ± 4.24 (years). The most common cause of ESRF 
in our patients was hypertension (34.6 %) followed by chronic glomerulonephritis (17.6 %), diabetes mellitus (12.8 %), 
obstructive uropathy (9.6 %), autosomal dominant poly cystic kidney disease (ADPKD) (4.7 %), chronic pyelonephritis 
(4.6 %), analgesic nephropathy (3.5 %). However in (10.7 %) no cause was found. In patient aged less than 40 years old 
the leading cause of ESRF was glomerulonephritis (29.3 %) followed by hypertension (25 %). In patient aged between 
40 to 60 years old the leading cause of ESRF was hypertension (38.5 %) followed by diabetes mellitus (14 %). In patient 
aged older than 60 years the leading cause of ESRF was hypertension (38.4 %) followed by diabetes mellitus (23.3 %).
Conclusions: ESRF in Sudan affects the economically productive age group; unemployment rate among ESRF 
patients is high. The study showed that hypertension is a leading cause of ESRF in Sudan followed by chronic glomer-
ulonephritis. Hypertension and diabetes mellitus are the leading causes of ESRF among patients over 40 years old.
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Background
End stage renal failure (ESRF) has become a major health 
problem in Sub Saharan Africa (SSA). There are limited 
data on the prevalence and incidence of ESRF in SSA due 
to lack of renal registries. Several studies pointed out to 
the magnitude of the problem in SSA. In Nigeria a study 
reported an increase of hospital admissions because of 
ESRF from 6 to 16  % between the years 1989 and 2003 
[1]. In Senegal only 8.23 % of ESRF patients receive renal 
replacement therapy (RRT) [2]. In Ghana, a study pointed 
out that 5 % of total hospital admissions had renal disease 
of whom 27.1 % died, usually of ESRF [3]. Hypertension 
is a leading cause of ESRF in Senegal and Ghana [4, 5] 
while chronic glomerulonephritis is the leading cause in 
South Africa and Ivory Coast [6, 7].
In Sudan, the estimated incidence of new cases of ESRF 
patients is 70–140 per million inhabitants/year [8]. There 
were limited data about causes of ESRF in Sudan. A small 
study conducted in Sudan among 61 patients in 1987 
reported that the causes of chronic kidney disease (CKD) 
are chronic glomerulonephritis, obstructive nephropa-
thy, hypertension and diabetes mellitus in that order [9]. 
Furthermore in study conducted among 100 Sudanese 
patients, chronic glomerulonephritis was found to be 
the leading cause of ESRF [10]. Other study conducted 
in central Sudan in 2009 among 224 ESRF patients found 
that hypertension (14.3  %) is a leading cause of ESRF 
followed by obstructive uropathy (11.6  %), glomerulo-
nephritis (9.8  %), diabetes mellitus (8  %), however in 
(53.57 %) no cause was found [11]. The aim of this study 
is to update and outline the causes of ESRF in Sudan.
Methods
Study population and data collection
This study is a cross sectional hospital based descriptive 
study. The subjects are ESRF adults’ patients on regu-
lar haemodialysis treatment in 15 haemdoialysis centres 
in Khartoum/Sudan. All patients on regular haemodi-
alysis were studied in November 2014 and interviewed 
by questionnaire focusing on personal and clinical data 
including (age, address, origin, employment, duration of 
dialysis, cause of ESRF). The medical files of each patient 
were reviewed to identify the cause of ESRF.
Concerning the causes of ESRF, diabetes was diag-
nosed based on the past medical history and result of 
the glucose tolerance test, hypertension was diagnosed 
based on past history of hypertension based on blood 
pressure of more than 140/90  mmHg, glomerulone-
phritis was diagnosed based on results of previous kid-
ney biopsies and on clinical grounds, polycystic kidney 
disease and obstructive uropathy were diagnosed based 
on abdominal ultrasound and other imaging modalities, 
sickle cell anaemia was diagnosed based on the result 
of haemoglobin electrophoresis, systemic lupus erythe-
matosus was diagnosed based on the clinical criteria in 
addition to lab results of auto antibodies, and analgesic 
nephropathy was diagnosed based on past medical his-
tory of chronic analgesic drugs usage with no other iden-
tifiable risk factors.
The research was in compliance of declaration of Hel-
sinki and approved by ethics and research committees 
in the Ministry of Health/Sudan and local hospitals. An 
informed consent was obtained from each patient par-
ticipated in the study.
Inclusion and exclusion criteria
We included all haemodialysis patients in 15 haemodialy-
sis centres in Khartoum/Sudan between (1/11/2014 and 
1/12/2014). We excluded haemodialysis patients less than 
18 years old.
Statistical analysis
Data were analyzed using SPSS 21; results were presented 
in number, percent, mean and standard deviation.
Results
A total of 1583 ESRF patients participated in the study. 
The characteristics of the study population are shown in 
Table  1. The results showed that the mean age of ESRF 
Patients was 49 ± 15.8 (years) and 63.4 % were male and 
76.3 % were unemployed. The mean duration of haemo-
dialysis is 4.38 ± 4.24 (years).
The aetiology of ESRF is shown in Table  2. The most 
common cause of ESRF in our patients was hyperten-
sion (34.6  %) followed by chronic glomerulonephritis 
(17.6 %), diabetes mellitus (12.8 %), obstructive uropathy 
(9.6  %), autosomal dominant poly cystic kidney disease 
(ADPKD) (4.7  %), chronic pyelonephritis (4.6  %), anal-
gesic nephropathy (3.5 %). However in (10.7 %) no cause 
was found.
In patient aged less than 40  years old the leading 
cause of ESRF was glomerulonephritis (29.3 %) followed 
by hypertension (25  %). In patient aged between 40 to 
60 years old the leading cause of ESRF was hypertension 
(38.5 %) followed by diabetes mellitus (14 %). In patient 
aged older than 60 years the leading cause of ESRF was 
hypertension (38.4  %) followed by diabetes mellitus 
(23.3  %). The study showed significant relation between 
age and some aetiologies of ESRF, glomerulonephritis, 
chronic pyelonephritis, sickle cell anaemia and congeni-
tal disease are tend to cause ESRF in younger patients 
while diabetes mellitus, hypertension and polycystic kid-
ney disease are significantly cause ESRF in older patients 
(Table 3).
We found no regional differences in causes of ESRF in 
Sudan (Table 4).
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Discussion
Characteristics of study population
CKD is at least 3–4 times more frequent in Africa than 
in developed countries [12]. Haemodialysis treatment in 
Sudan is free and paid by the government. There are lim-
ited data on the prevalence and causes of ESRF in Sudan 
apart from few studies. This study included a large popu-
lation of ESRF patients.
CKD in SSA tends to affect relatively younger individu-
als [13]. Our result showed that the mean age of ESRF 
patients is 49 ± 15.8 (years) and 47.9 % of ESRF patients 
are below an age of 50 years. This indicates that ESRF in 
Sudan affects the economically productive age group, 
unlike the situation in many developed countries were 
the mean age of ESRF patients is generally over 60 years 
[14].
In this study males constitute 63  % of ESRF patients 
receiving haemodialysis treatment; this is similar to many 
of other study conducted in Africa, in Ethiopia males 
constitute 61.5 % of ESRF patients receiving dialysis [15], 
in Ivory Coast males constitute 61 % of patients [16].
Several studies pointed out an increase rate of unem-
ployment among haemodialysis patients [17, 18]. In our 
study 76.3  % of ESRF patients receiving haemodialysis 
treatment were unemployed; this reflect the financial 
burden on families of patients on haemodialysis espe-
cially in an African country like Sudan.
Causes of ESRF
In the current study hypertension is a leading cause of 
ESRF as it is a leading cause in many of SSA countries 
[4, 5]. Other study conducted in central Sudan in 2009 
among 224 patients found that hypertension is a lead-
ing cause of ESRF [11]. Hypertension is considered to be 
a common health problem in SSA. 33  % of the general 
population in Malawi were found to be hypertensive [19]. 
In Uganda the prevalence of hypertension was 22.1  % 
in men and 20.5 % in women [20]. In Nigeria, 20.8 % of 
general population found to be hypertensive [21]. Hyper-
tension in SSA has been mounting over the past few 
decades. A meta analysis of studies conducted between 
2000 and 2013 in SSA found that only 18 % of individuals 
with hypertension were receiving treatment and only 7 % 
had controlled blood pressure [22]. In other community 
based Sudanese survey conducted in 2012 found that the 
prevalence of hypertension in rural areas was 15.8 and 
45 % had uncontrolled blood pressure [23].
In this study, chronic glomerulonephritis was found to 
be the second most frequent cause of ESRF. The previous 
two published studies conducted in Sudan on 1987 and 
1989 found that chronic glomerulonephritis is a lead-
ing cause of ESRF [9, 10], however both studies were 
conducted in one centre with small study samples. Our 
results are relevant to many of SSA where the glomeru-
lonephritis was found to be the second leading cause of 
ESRF. In Nigeria, 27.8 % of causes of ESRF is attributed 
to chronic glomerulonephritis [1]. In Ghana, glomeru-
lonephritis is a second leading cause of ESRF [5]. In 
Senegal, 16  % of ESRF patients are due to chronic glo-
merulonephritis and consider to be the second leading 
cause of ESRF following hypertension [4]. The situation 
Table 1 The characteristics of the study population
a Number (percentage)
b Mean ± SD
Age (years)b 49 ± 15.8
Gendera
 Male 1004 (63.4 %)
 Female 579 (36.6 %)
Occupationa
 Unemployed 1208 (76.3 %)
 Non professional 238 (15.0 %)
 Professional 137 (8.4 %)
Origina
 Northern Sudan 438 (27.7 %)
 Central Sudan 417 (26.3 %)
 Western Sudan (Kordofan) 270 (17.1 %)
 Western Sudan (Darfour) 144 (9.1 %)
 Eastern Sudan 53 (3.3 %)
 Khartoum 261 (16.5 %)
Addressa
 Khartoum 624 (39.4 %)
 Omdurman 547 (34.6 %)
 Khartoum North 230 (14.5 %)
 East Nile 147 (9.3 %)
 Outside Khartoum 35 (2.2 %)
Duration of haemodialysis (years)b 4.38 ± 4.24
Table 2 Causes of  end stage renal failure among  study 
population
Data are numbers (percent)
Hypertensive nephropathy 547 (34.6 %)
Glomerulonephritis 278 (17.6 %)
Diabetic nephropathy 203 (12.8 %)
Obstructive uropathy 152 (9.6 %)
Polycystic kidney disease 74 (4.7 %)
Chronic pyelonephritis 73 (4.6 %)
Analgesic nephropathy 56 (3.5 %)
Congenital and hereditary diseases 15 (0.9 %)
Systemic lupus erytherematosus 9 (0.6 %)
Sickle cell anaemia 7(0.4 %)
Unknown 169 (10.7 %)
Total 1583 (100 %)
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is different in South Africa where glomerulonephritis is a 
leading cause of ESRF [6].
Our result showed that diabetes mellitus was found 
to be the second leading cause of ESRF among patients 
over 40  years old. There are limited data on prevalence 
of diabetes mellitus in Sudan. A community based study 
conducted in Sudan in 1996 conducted among 1284 sub-
jects found that prevalence of diabetes mellitus was 3.4 % 
Table 3 Causes of end stage renal failure according to age
Data are numbers (percent)
Causes of end stage renal  
failure
<40 years (n = 463) 40–60 years (n = 716) >60 years (n = 404) P value
Count % Count % Count %
Glomerulonephritis 136 29.4 100 14.0 42 10.4 0.000
Hypertensive nephropathy 116 25.1 276 38.5 155 38.4 0.000
Obstructive uropathy 42 9.1 77 10.8 33 8.2 0.333
Chronic pyelonephritis 39 8.4 20 2.8 14 3.5 0.000
Analgesic nephropathy 19 4.1 26 3.6 11 2.7 0.538
Diabetic nephropathy 10 2.2 99 13.8 94 23.3 0.000
Congenital and hereditary diseases 9 1.9 5 0.7 1 0.2 0.024
Polycystic kidney disease 8 1.7 50 7 16 4 0.0001
Sickle cell anaemia 6 1.3 0 0 1 0.2 0.004
Systemic lupus erythematosus 4 0.9 4 0.6 1 0.2 0.484
Unknown 74 16 59 8.2 36 8.9 0.0001
Table 4 Causes of end stage renal failure according to region
Causes Region Total





Hypertension 146 132 112 43 16 98 547
33.3 % 31.7 % 41.5 % 29.9 % 30.2 % 37.5 % 34.6 %
Diabetes mellitus 74 53 23 11 6 36 203
16.9 % 12.7 % 8.5 % 7.6 % 11.3 % 13.8 % 12.8 %
Glomerulonephritis 69 73 48 37 7 44 278
15.8 % 17.5 % 17.8 % 25.7 % 13.2 % 16.9 % 17.6 %
Obstructive uropathy 41 49 21 18 8 15 152
9.4 % 11.8 % 7.8 % 12.5 % 15.1 % 5.7 % 9.6 %
Polycystic kidney disease 27 17 7 4 4 15 74
6.2 % 4.1 % 2.6 % 2.8 % 7.5 % 5.7 % 4.7 %
Chronic pyelonephritis 20 15 13 5 5 15 73
4.6 % 3.6 % 4.8 % 3.5 % 9.4 % 5.7 % 4.6 %
Analgesic nephropathy 8 18 12 6 1 11 56
1.8 % 4.3 % 4.4 % 4.2 % 1.9 % 4.2 % 3.5 %
Systemic lupus  
erythrematosus
5 1 2 0 1 0 9
1.1 % 0.2 % 0.7 % 0.0 % 1.9 % 0.0 % 0.6 %
Sickle cell anaemia 1 1 3 0 1 1 7
0.2 % 0.2 % 1.1 % 0.0 % 1.9 % 0.4 % 0.4 %
Congenital and  
hereditary diseases
10 4 0 0 0 1 15
2.3 % 1.0 % 0.0 % 0.0 % 0.0 % 0.4 % 0.9 %
Unknown 37 54 29 20 4 25 169
8.4 % 12.9 % 10.7 % 13.9 % 7.5 % 9.6 % 10.7 %
Total 438 (100 %) 417 (100 %) 270 (100 %) 144 (100 %) 53 (100 %) 261 (100 %) 1583 (100 %)
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[24]. Other study conducted in Dongola in North Sudan 
found that prevalence of diabetes mellitus was 8.3 % [25]. 
Diabetes is the leading cause of ESRF in Latin America 
[26] and in UK black patients [27]. In USA, the incidence 
of ESRF due to diabetes was 2.6 fold higher among blacks 
[28]. Diabetes is a second leading cause of ESRF in many 
of SSA like in Nigeria [29] and in Senegal [30]. The preva-
lence of diabetic nephropathy in SSA is estimated to be 
14–16 % in South Africa, 23.8 % in Zambia, 9 % in Sudan, 
and 6.1 % in Ethiopia [12].
Analgesic nephropathy accounted for a significant 
minority of causes of ESRF in Sudan. This is because the 
excessive use of analgesia without doctor’s prescription. 
Analgesic nephropathy first attributed to the habitual use 
of phenacetin-containing analgesics [31]. Several studies 
pointed out that an excessive use of analgesic mixtures 
containing acetaminophen, aspirin, caffeine, or codeine 
also can be associated with analgesic nephropathy and 
eventually ESRF [32, 33]. Several studies also pointed out 
to the association between the use of single-ingredient 
analgesics containing acetaminophen or aspirin and CKD 
[34–36]. A Swedish study conducted in 2001 found that 
the regular use of acetaminophen or aspirin was associ-
ated with a risk of chronic renal failure that was 2.5 times 
as high as that for nonusers [37]. An American study 
found that patients use non steroidal anti inflammatory 
drugs (NSAID) in daily bases were associated with two-
fold increase risk for CKD [38]. NSAID have been associ-
ated with nephrotic syndrome, interstitial nephritis and 
ESRF [39], despite that patient with CKD should avoid 
the use of NSAID, still studies found that CKD awareness 
was not associated with reduction of NSAID usage [40].
In our study, 4.7 % of ESRF patients receiving dialysis 
are due to autosomal dominant polycystic kidney disease 
(ADPKD) and it remains the leading hereditary cause of 
ESRF in Sudan. Results obtained from European regis-
tries stated that ADPKD constitute about 9.8 % of ESRF 
patients receiving RRT [41]. There were limited data 
about prevalence of ADPKD in Africa. Our data is similar 
to other African studies. In Morocco, 6.5 % of patients on 
dialysis are due to ADPKD [42] similar to Libya which is 
6.3 % [43]. A hospital study conducted in Senegal found 
that prevalence of ADPKD was one in 250 patients fol-
lowing in Nephrology Department [44].
Small percentage of adult ESRF patients receiving RRT 
in Sudan is due to sickle cell anemia. Despite sickle cell 
anaemia is common in Sudan however they die early. 
Sickle cell anaemia is associated with renal ischemia, glo-
merulonephritis, nephrotic syndrome and ESRF [45, 46]. 
There is limited data on sickle cell nephropathy in SSA. 
In USA, 0.11 % of ESRF patients receiving renal replace-
ment therapy are due to sickle cell anemia and 93 % were 
African–Americans [47].
In our study, we couldn’t identify a known cause of 
ESRF in 10.7 % of patients. This is mostly because of late 
presentation of patients to the nephrology departments 
and lack of medical facilities and poor medical follow up 
of patients in rural areas.
The strength of this study is the inclusion of all ESRF 
patients receiving haemodialysis treatment in 15 haemodi-
alysis units in Khartoum State/Sudan with a total of 1583 
patients participated in the study makes our study has a 
large sample size, putting in mind that 60 % of ESRF patients 
in Sudan receive RRT in Khartoum State. Our study has 
limitations that need to be addressed. In our study, hyper-
tension is a leading cause of ESRF, but in some cases it was 
difficult to determine is it primary hypertension or second-
ary to CKD itself? This is because of lack of regular medi-
cal follow up in our patients. Other point which need to be 
discussed is that in this study, identifications of diabetes and 
hypertension as an aetiology of ESRF can be overestimated, 
lack of kidney biopsies from these patients that needed it to 
make sure that there is no other cause of ESRF and make 
an exact determination of the aetiology of ESRF is difficult, 
this is because of late presentation of patients and lack of 
resources. Many studies conducted in developing countries 
used the same criteria we used to determine the aetiology 
of ESRF [48, 49]. Other limitation is that sometimes the 
medical data about the exact nature of the cause of ESRF 
are not available especially data regarding kidney biopsies 
which made the percentage of the unknown cause is slightly 
increased in our study. In addition, our study conducted in 
haemodialysis patients but there is no available data about 
ESRF patients not on RRT.
Conclusions
ESRF in Sudan affects the economically productive age 
group; unemployment rate is high among ESRF patients. 
The study showed that hypertension is a leading cause 
of ESRF in Sudan followed by chronic glomerulonephri-
tis. Hypertension and diabetes mellitus are the leading 
causes of ESRF among patients over 40 years old.
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